Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

enues for the nine months ended September 30, 2008 consisted of $26.5 million in royalty revenue compared with $14.5 million for the same prior year period. Royalty revenue is earned pursuant to the license agreement entered into with MGI PHARMA. The Company recognizes royalty revenue on a cash basis when it is received. There was no net product revenue for the nine months ended September 30, 2008 compared with $621,000 for the same prior year period. The decrease in net product revenue during 2008 is due to the sale of the Company's worldwide rights for Nipent to Mayne Pharma in a prior calendar year.

Excluding gain on sale of products, total costs and operating expenses for the nine months ended September 30, 2008 were $33.4 million compared with $37.7 million for the same prior year period. The primary reason for the decrease in total costs and operating expenses for the nine months ended June 30, 2008 were lower acquired in-process research and development costs, a reduction in ongoing general and administrative costs related to winding down our European operations and lower stock-based compensation expense offset in part by higher research and development costs related to increased product development activities including ongoing clinical operations and payment of severance costs in the amount of $420,000 related to the closure of our European operation. Stock-based compensation expense, which is included in operating expenses, was $2.1 million for the nine months ended September 30, 2008 compared with $3.2 million for the same prior year period. The gain on sale of products for the nine months ended September 30, 2008 was $1.6 million compared with $27.7 million for the same prior year period.

Loss from operations for the nine months ended September 30, 2008 was $5.3 million compared with income from operations of $5.1 million for the same prior year period. The Company reported a net loss for the nine months ended September 30, 2008 of $6.5 mill
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... with certain shareholders representing approximately 45% of the outstanding ... certain matters including the appointment of auditors at its ... 2015 (the "Meeting") it intends to adjourn the Meeting ... when the Meeting reconvenes. The Meeting will be reconvened ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... San Francisco, CA (PRWEB) March 25, 2015 ... Provide Support for Novel Mechanism of Action in ... March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) ... its fast skeletal muscle troponin activator tirasemtiv in ... from a Phase IIa “Evidence of Effect” or ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... , , ... , , , ... example protein arrays) or as biopharmaceutical therapeutics. In,all cases the ... key quality criteria include: protein identification,quantitation and the monitoring of ...
... , ... , , , When working ... transfection of small interfering RNA (siRNA),into a cell, the presence of having ... be of great value.,Three to four siRNA sequences are generally tested for ...
... , , ... , , This Application Note ... can be used to detect cell surface,and intracellular protein targets by ... on CCRF-CEM cells and intracellular,glucocorticoid receptor (GR) staining of H4 rat ...
Cached Biology Technology:Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 2Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 3siRNA transfection optimization,with the Agilent 2100 bioanalyzer 2siRNA transfection optimization,with the Agilent 2100 bioanalyzer 3siRNA transfection optimization,with the Agilent 2100 bioanalyzer 4siRNA transfection optimization,with the Agilent 2100 bioanalyzer 5siRNA transfection optimization,with the Agilent 2100 bioanalyzer 6siRNA transfection optimization,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 2Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 3Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 4Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 5Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 6Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 8
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2
... detection is critical for improving cancer survival rates. Yet, ... lung cancer, is notoriously difficult to detect in its ... to detect lung cancer by merely shining diffuse light ... new clinical study, the analysis technique--called partial wave spectroscopic ...
... Many scientists aspire to take control over the stem cell ... perfectly matched to each patient in the future. Now research ... SAGE-Hindawi, explains how engineering the topography on which stem cells ... as powerful an agent for change as their chemical environment. ...
... BOZEMAN, Mont. -- Invasive plants make life tougher for ... of the Missouri River Basin, so why not turn the ... time? Russian olive and saltcedar alone could supply biomass ... region. Converting invasive plants to fuel is an ...
Cached Biology News:Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Stem cells shape up to their surroundings 2Stem cells shape up to their surroundings 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
... discovery races ever faster, you need a partner ... So our constant focus is on providing tools ... why our Biomek 3000 Laboratory Automation Workstation offers ... it is flexible. By integrating all aspects of ...
Biology Products: